莫西沙星在慢性阻塞性肺疾病急性加重期的应用进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

邓聪 ,  曹晓红

山西医科大学（山西汾阳 030000）;

Corresponding author：

曹晓红, Email: caoxhong@sina.com

Keywords：

DOI：

10.7507/1671-6205.201902044

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 邓聪, 曹晓红. 莫西沙星在慢性阻塞性肺疾病急性加重期的应用进展. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(4): 414-417. doi: 10.7507/1671-6205.201902044 Copy

1.	GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018[EB/OL]. [2018-07-17]. https://goldcoped.org/.
2.	Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res, 2013, 14(1): 1-9.
3.	Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
4.	慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017 年更新版). 国际呼吸杂志, 2017, 37(14): 1041-1057.
5.	刘丽, 张春燕, 邱镞文. 慢性阻塞性肺疾病急性加重期呼吸道病毒感染检出率及危险因素分析. 临床肺科杂志, 2018, 23(6): 1118-1122.
6.	Alberto P, Cinzia MB, Fausto B, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006, 173(10): 1114-1121.
7.	Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2018, 10: CD010257.
8.	Woodhead M, Blasi F, Ewig S, et al. Guidelines for the Management of Adult Lower Respiratory Tract Infections. Clin Microbiol Infect, 2011, 17(s6): 1-24.
9.	Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006, 173(9): 991-998.
10.	肖琴锋. COPD 患者下呼吸道感染的病原菌分布及耐药性分析. 浙江临床医学, 2018, (1): 148-150.
11.	Sionidou M, Manika K, Pitsiou G, et al. Moxifloxacin in chronic obstructive pulmonary disease: pharmacokinetics and penetration into bronchial secretions in ward and intensive care unit patients. Antimicrob Agents Chemother, 2019, 63(3): 1974-1918.
12.	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
13.	Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J, 2009, 34(5): 1066-1071.
14.	Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res, 2010, 11: 10.
15.	Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax, 2015, 70(10): 930-938.
16.	Schild K, Knobloch J, Yakin Y, et al. IL-5 release of CD4+ non-effector lymphocytes is increased in COPD--modulating effects of moxifloxacin and dexamethasone. Int Immunopharmacol, 2011, 11(4): 444-448.
17.	Chuchalin A, Zakharova M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulm Med, 2013, 13: 5.
18.	Sethi S, Anzueto A, Miravitlles M, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection, 2016, 44(1): 65-76.
19.	Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J, 2012, 40(1): 17-27.
20.	Minov J, Stoleski S, Petrova T, et al. Moxifloxacin in the outpatient treatment of moderate exacerbations of chronic obstructive pulmonary disease. Open Access Maced J Med Sci, 2018, 6(11): 2017-2022.
21.	Miravitlles M, Llor C, Molina J, et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis, 2010, 5: 11-19.
22.	Miravitlles M, García-Polo C, Domenech A, et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung, 2013, 191(5): 523-530.
23.	Liu KX, Xu B, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis, 2014, 6(3): 221-229.
24.	谢根英, 何拉结, 吴荔嘉, 等. 莫西沙星与左氧氟沙星分别治疗慢性阻塞性肺疾病加重期疗效与安全性的系统评价. 中国医院用药评价与分析, 2013, 13(7): 594-598.
25.	林其昌, 刘凯雄, 刘少滨, 等. 莫西沙星治疗慢性阻塞性肺疾病急性加重疗效和安全性的多中心研究. 中华结核和呼吸杂志, 2015, 38(5): 366-369.
26.	陈有娥. 哌拉西林钠/他唑巴坦钠联合莫西沙星治疗 COPD 合并急性下呼吸道感染的临床观察. 实用临床医药杂志, 2015, 19(5): 18-21.
27.	伏俊, 房三友, 闻寅, 等. 美罗培南联合莫西沙星治疗慢性阻塞性肺病并发感染性肺炎的疗效分析. 中华实验和临床感染病杂志(电子版), 2015, (1): 73-76.
28.	王媛媛, 刘丽萍, 操艺, 等. 莫西沙星序贯治疗老年社区获得性肺炎的药物经济学评价. 安徽医药, 2012, 16(2): 226-228.
29.	覃演秋. 雾化吸入莫西沙星治疗慢性阻塞性肺疾病合并呼吸衰竭 92 例的临床分析. 数理医药学杂志, 2015, (10): 1499-1500.

1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018[EB/OL]. [2018-07-17]. https://goldcoped.org/.
2. Donaldson GC, Müllerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res, 2013, 14(1): 1-9.
3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
4. 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017 年更新版). 国际呼吸杂志, 2017, 37(14): 1041-1057.
5. 刘丽, 张春燕, 邱镞文. 慢性阻塞性肺疾病急性加重期呼吸道病毒感染检出率及危险因素分析. 临床肺科杂志, 2018, 23(6): 1118-1122.
6. Alberto P, Cinzia MB, Fausto B, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 2006, 173(10): 1114-1121.
7. Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2018, 10: CD010257.
8. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the Management of Adult Lower Respiratory Tract Infections. Clin Microbiol Infect, 2011, 17(s6): 1-24.
9. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2006, 173(9): 991-998.
10. 肖琴锋. COPD 患者下呼吸道感染的病原菌分布及耐药性分析. 浙江临床医学, 2018, (1): 148-150.
11. Sionidou M, Manika K, Pitsiou G, et al. Moxifloxacin in chronic obstructive pulmonary disease: pharmacokinetics and penetration into bronchial secretions in ward and intensive care unit patients. Antimicrob Agents Chemother, 2019, 63(3): 1974-1918.
12. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med, 2011, 365(8): 689-698.
13. Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J, 2009, 34(5): 1066-1071.
14. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res, 2010, 11: 10.
15. Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax, 2015, 70(10): 930-938.
16. Schild K, Knobloch J, Yakin Y, et al. IL-5 release of CD4+ non-effector lymphocytes is increased in COPD--modulating effects of moxifloxacin and dexamethasone. Int Immunopharmacol, 2011, 11(4): 444-448.
17. Chuchalin A, Zakharova M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC Pulm Med, 2013, 13: 5.
18. Sethi S, Anzueto A, Miravitlles M, et al. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection, 2016, 44(1): 65-76.
19. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J, 2012, 40(1): 17-27.
20. Minov J, Stoleski S, Petrova T, et al. Moxifloxacin in the outpatient treatment of moderate exacerbations of chronic obstructive pulmonary disease. Open Access Maced J Med Sci, 2018, 6(11): 2017-2022.
21. Miravitlles M, Llor C, Molina J, et al. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. Int J Chron Obstruct Pulmon Dis, 2010, 5: 11-19.
22. Miravitlles M, García-Polo C, Domenech A, et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung, 2013, 191(5): 523-530.
23. Liu KX, Xu B, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis, 2014, 6(3): 221-229.
24. 谢根英, 何拉结, 吴荔嘉, 等. 莫西沙星与左氧氟沙星分别治疗慢性阻塞性肺疾病加重期疗效与安全性的系统评价. 中国医院用药评价与分析, 2013, 13(7): 594-598.
25. 林其昌, 刘凯雄, 刘少滨, 等. 莫西沙星治疗慢性阻塞性肺疾病急性加重疗效和安全性的多中心研究. 中华结核和呼吸杂志, 2015, 38(5): 366-369.
26. 陈有娥. 哌拉西林钠/他唑巴坦钠联合莫西沙星治疗 COPD 合并急性下呼吸道感染的临床观察. 实用临床医药杂志, 2015, 19(5): 18-21.
27. 伏俊, 房三友, 闻寅, 等. 美罗培南联合莫西沙星治疗慢性阻塞性肺病并发感染性肺炎的疗效分析. 中华实验和临床感染病杂志(电子版), 2015, (1): 73-76.
28. 王媛媛, 刘丽萍, 操艺, 等. 莫西沙星序贯治疗老年社区获得性肺炎的药物经济学评价. 安徽医药, 2012, 16(2): 226-228.
29. 覃演秋. 雾化吸入莫西沙星治疗慢性阻塞性肺疾病合并呼吸衰竭 92 例的临床分析. 数理医药学杂志, 2015, (10): 1499-1500.

Previous Article
肠道 EB 病毒相关淋巴组织增殖性疾病误诊为肠结核一例
Next Article
以机械功为导向的急性呼吸窘迫综合征机械通气新理念

Chinese Journal of Respiratory and Critical Care Medicine

莫西沙星在慢性阻塞性肺疾病急性加重期的应用进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content